£77.81

Springer Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on ... 13, 1984: 27 (Developments in Oncology, 27)

Price data last checked 50 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

About as cheap as it gets. The only time it was cheaper was 3 months ago.

£78 today · all-time low £78 (May 2026) · usually the usual

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 41 days · 41 data points (no recent data)

Historical
Generating forecast…
£77.82 £77.75 £77.77 £77.78 £77.80 £77.81 £77.83 21 May 2026 31 May 2026 10 June 2026 20 June 2026 30 June 2026

Price Distribution

Price distribution over 41 days • 1 price levels

Days at Price
41 days 0 10 21 31 41 £78 Days at Price

Price Analysis

Most common price: £78 (41 days, 100.0%)

Price range: £78 - £78

Price levels: 1 different prices over 41 days

Description

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

Product Specifications

Format
paperback
Domain
Amazon UK
Publication Date
05 October 2011
Listed Since
21 December 2012

Barcode

No barcode data available

Similar Products You Might Like

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on ... 13, 1984: 27 (Developments in Oncology, 27)
99% match

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation: Proceedings of the Symposium held in Adjunction with the Second International Conference on ... 13, 1984: 27 (Developments in Oncology, 27)

Springer

£83.30 11 Jul 2026
Interferon and Cancer
96% match

Interferon and Cancer

Springer

£73.87 13 Jul 2026
Interferons: Characterization and Clinical Applications Book
95% match

Interferons: Characterization and Clinical Applications Book

Nova Science Publishers Inc

£142.99 16 Jul 2026
Viruses and Interferon: Current Research
95% match

Viruses and Interferon: Current Research

Caister Academic Press Limited

£199.00 10 Jul 2026
Infections Related to Biologics, An Issue of Infectious Disease Clinics of North America: Volume 34-2 (The Clinics: Internal Medicine, Volume 34-2)
95% match

Infections Related to Biologics, An Issue of Infectious Disease Clinics of North America: Volume 34-2 (The Clinics: Internal Medicine, Volume 34-2)

Elsevier

£69.09 08 Jul 2026
Cancer Immunology: Innovative Approaches to Therapy: 27 (Cancer Treatment and Research)
95% match

Cancer Immunology: Innovative Approaches to Therapy: 27 (Cancer Treatment and Research)

Springer

£165.42 03 Jul 2026
Cancer Immunology: Innovative Approaches to Therapy: 27 (Cancer Treatment and Research, 27)
95% match

Cancer Immunology: Innovative Approaches to Therapy: 27 (Cancer Treatment and Research, 27)

Springer

£168.12 13 Jul 2026
Bacterial Activation of Type I Interferons
95% match

Bacterial Activation of Type I Interferons

Springer

£74.86 13 Jul 2026
Springer - Novel Immunotherapeutic Approaches to Cancer Treatment
95% match

Springer - Novel Immunotherapeutic Approaches to Cancer Treatment

Springer

£108.91 16 Jul 2026
Springer - Novel Immunotherapeutic Approaches to Cancer Treatment
95% match

Springer - Novel Immunotherapeutic Approaches to Cancer Treatment

Springer

£113.97 15 Jul 2026
Immune Mediators in Cancer: Methods and Protocols: 2108 (Methods in Molecular Biology)
95% match

Immune Mediators in Cancer: Methods and Protocols: 2108 (Methods in Molecular Biology)

Humana

£89.34 03 Jul 2026
Infection and Cancer: Bi-Directorial Interactions
94% match

Infection and Cancer: Bi-Directorial Interactions

Springer

£109.24 08 Jul 2026
Burkitt Lymphoma: Updates in Etiology, Symptoms, Molecular Genetics and Treatment Options
94% match

Burkitt Lymphoma: Updates in Etiology, Symptoms, Molecular Genetics and Treatment Options

£192.99 04 Jul 2026
OSH Infection in the Immunocompromised Host (Oxford Specialist Handbooks)
94% match

OSH Infection in the Immunocompromised Host (Oxford Specialist Handbooks)

Oxford University Press

£49.36 04 Jul 2026
Tumor Immunology: Methods and Protocols: 1393 (Methods in Molecular Biology, 1393)
94% match

Tumor Immunology: Methods and Protocols: 1393 (Methods in Molecular Biology, 1393)

Humana

£69.36 07 Jul 2026
Negative Co-Receptors and Ligands: 350 (Current Topics in Microbiology and Immunology, 350)
94% match

Negative Co-Receptors and Ligands: 350 (Current Topics in Microbiology and Immunology, 350)

Springer

£96.02 09 Jul 2026
Academic Press - Multifaceted Role of IL-1 in Cancer and Inflammation
94% match

Academic Press - Multifaceted Role of IL-1 in Cancer and Inflammation

Academic Press

£114.99 15 Jul 2026
Prognostic and Therapeutic Applications of RKIP in Cancer
94% match

Prognostic and Therapeutic Applications of RKIP in Cancer

Academic Press

£98.69 09 Jul 2026
Epstein-Barr Virus: Latency and Transformation
94% match

Epstein-Barr Virus: Latency and Transformation

Caister Academic Press Limited

£199.00 13 Jul 2026
Infectious Agents Associated Cancers: Epidemiology and Molecular Biology: 1018 (Advances in Experimental Medicine and Biology, 1018)
94% match

Infectious Agents Associated Cancers: Epidemiology and Molecular Biology: 1018 (Advances in Experimental Medicine and Biology, 1018)

Springer

£108.33 04 Jul 2026
Humana Cancer Immunosurveillance: Methods and Protocols 1884
94% match

Humana Cancer Immunosurveillance: Methods and Protocols 1884

Humana

£104.44 15 Jul 2026
CRC Press - Interferon and Nonviral Pathogens: 42 (Immunology)
94% match

CRC Press - Interferon and Nonviral Pathogens: 42 (Immunology)

CRC Press

£114.25 02 Jul 2026
Immunoconjugate Therapy of Hematologic Malignancies: 68 (Cancer Treatment and Research, 68)
94% match

Immunoconjugate Therapy of Hematologic Malignancies: 68 (Cancer Treatment and Research, 68)

Springer

£179.99 13 Jul 2026
Advances in Cancer Research: 84: Volume 84
94% match

Advances in Cancer Research: 84: Volume 84

Academic Press

£29.20 09 Jul 2026